Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb double-blind randomized placebo-controlled trial of norursodeoxycholic acid in NASH
2018-003443-31Phase 2Completed
- Sponsor
- Dr. Falk Pharma GmbH
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of norursodeoxycholic acid in metabolic dysfunction-associated steatohepatitis (MASH) (3 arms), sponsored by Dr. Falk Pharma GmbH. Primary endpoint: Resolution of NASH without worsening of fibrosis. Started Mar 2019; status: completed.
02
Drugs
norursodeoxycholic acid
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on 2018-003443-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003443-31.